SCHEMBL4350086

SCHEMBL4350086

CCSc1ccccc1CNc1cccc(F)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.44
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
GAA P10253 4/20 0.42
LMNA P02545 4/20 0.42
KMT2A Q03164 6/20 0.42
MAPT P10636 5/20 0.42
KDM4E B2RXH2 5/20 0.42
MEN1 O00255 5/20 0.42
ALDH1A1 P00352 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
HSD17B10 Q99714 2/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
ADRA2A P08913 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41
ADRA1D P25100 2/20 0.41
ADRA1A P35348 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343471 0.86 CA12 (0.37) L3MBTL1CA12CA2CA9GAA
SCHEMBL4357389 0.84 CA12 (0.41) L3MBTL1CA12CA2CA9GAA
SCHEMBL4346851 0.82 L3MBTL1 (0.42) L3MBTL1GAALMNAKMT2AMAPT
SCHEMBL4348421 0.82 SMN1; SMN2 (0.43) L3MBTL1CA12CA2CA9GAA
SCHEMBL4342190 0.80 SLC6A2 (0.43) L3MBTL1CA12CA2CA9GAA
SCHEMBL4357641 0.80 LMNA (0.42) L3MBTL1CA12CA2CA9GAA
SCHEMBL4355501 0.78 SLC6A4 (0.46) L3MBTL1CA12CA2CA9GAA
SCHEMBL4349903 0.77 MEN1 (0.58) L3MBTL1GAALMNAKMT2AMAPT
SCHEMBL4347402 0.77 MAPT (0.45) L3MBTL1GAAKMT2AMAPTKDM4E
SCHEMBL4354085 0.77 SLC6A4 (0.51) L3MBTL1CA12CA2CA9GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 L3MBTL1 1972/4885CA12 2054/4885CA2 2053/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 L3MBTL1 2528/4885CA12 2458/4885CA2 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.